[CAS NO. 18378-89-7] Plicamycin
PRODUCTS SPECIFICATIONS [18378-89-7]
DESCRIPTION [18378-89-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 1085.15 |
| Molecular Formula | C52H76O24 |
| SMILES | O=C([C@H]([C@@]([C@H](OC)C([C@@H](O)[C@H](O)C)=O)([H])C1)O[C@@](O[C@H](C)[C@H]2O)([H])C[C@H]2O[C@@](O[C@H](C)[C@@H]3O)([H])C[C@H]3O[C@@](O[C@H](C)[C@H]4O)([H])C[C@@]4(O)C)C(C1=CC5=CC(O[C@H](O[C@H](C)[C@H]6O)C[C@H]6O[C@@](O[C@H](C)[C@H]7O)([H])C[C@H]7O)=C(C)C(O)=C85)=C8O |
16 Publications Citing Use of MCE
- [1]Mol Cancer. 2022 Mar 18;21(1):77.
- [2]Nat Commun. 2023 Feb 9;14(1):731.
- [3]Theranostics. 2022 Jan 1;12(2):842-858.
- [4]Cell Death Dis. 2021 Oct 21;12(11):978.
- [5]Cell Biol Toxicol. 2020 Jul 12.
- [6]Cancer Immunol Immunother. 2021 Jun 22.
- [7]J Cell Mol Med. 2021 May 5.
- [8]Cancer Res Treat. 2021 Apr;53(2):506-527.
- [9]Genes (Basel). 2022, 13(3), 483.
- [10]J Cancer. 2022 Apr 11;13(7):2226-2237.
- [11]Toxicol Appl Pharmacol. 2021 Jun 1;115606.
- [12]Immunol Invest. 2022 Dec 23;1-17.
- [13]Research Square Print. November 8th, 2022
- [14]Research Square Print. 2020 May.
- [15]Research Square Preprint. 2021 Nov.
- [16]Research Square Preprint. 2021 Oct.
Summary
Plicamycin is a selective specificity protein 1 ( Sp1 ) inhibitor. Plicamycin inhibits the growth of various cancers by decreasing Sp1 protein.
IC50 & Target
Sp1 transcription factor [1]
In Vitro
Sp1 is a zinc-finger transcription factor that regulates multiple cellular functions and promotes tumor progression by controlling expression of genes involved in cell cycle, apoptosis and DNA damage. Sp1 binds to GC-rich motifs of promoters and interacts with components of the general transcriptional machinery and co-activator complexes of multiple signaling pathways. Plicamycin (Mith) decreases Sp1 protein by inducing proteasome-dependent degradation, thereby suppressing cervical cancer growth through a DR5/caspase-8/Bid signaling pathway. To assess the antiproliferative effects of Plicamycin on cervical cancer cells, two cervical cancer cell lines with different genetic backgrounds are grown with or without treatment with Plicamycin at different concentrations. Plicamycin inhibits HEp-2 and KB cell growth in a concentration-dependent manner after 48 h. Apoptotic cell death is qualitatively estimated by DAPI staining for nuclear condensation and fragmentation. Plicamycin leads to significant DNA fragmentation compared to untreated controls [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
The antitumorigenic activity of Plicamycin (0.2 mg/kg/day) is determined in a xenograft model and observed reduction in tumor volume and weight. No significant mouse body weight loss is observed in Plicamycin-treatment groups, indicating that Plicamycin-associated toxicity is minimal. Plicamycin also increases TUNEL-positive cells in tumor xenografts. No notable intergroup differences are observed among organs, indicating no marked signs of systemic toxicity at the Plicamycin dose used in this study [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 92.15 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 0.9215 mL | 4.6077 mL | 9.2153 mL |
| 5 mM | 0.1843 mL | 0.9215 mL | 1.8431 mL |
| 10 mM | 0.0922 mL | 0.4608 mL | 0.9215 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.30 mM); Clear solution
Synonyms